The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation-Reference-Cited by-同舟云学术

The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation

Published:2004-09 Issue:9 Volume:23 Page:806-814
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Law Barbara J.,Langley Joanne M.,Allen Upton,Paes Bosco,Lee David S. C.,Mitchell Ian,Sampalis John,Walti Hervé,Robinson Joan,O’Brien Karel,Majaesic Carina,Caouette Georges,Frenette Lyne,Le Saux Nicole,Simmons Brian,Moisiuk Sharon,Sankaran Koravanagattu,Ojah Cecil,Singh Avash J.,Lebel Marc H.,Bacheyie Godfrey S.,Onyett Heather,Michaliszyn Andrea,Manzi Patricia,Parison Diana

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology and Child Health

Reference27 articles.

1. The Prevention of Perinatal Mortality and Morbidity.,1970

2. The contribution of mild and moderate preterm birth to infant mortality: Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System.;Kramer;JAMA,2000

3. Rehospitalization for respiratory syncytial virus among premature infants.;Joffe;Pediatrics,1999

4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants.;Pediatrics,1998

5. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.;Boyce;J Pediatr,2000

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Retrospective Public Health Assessment and Management in Terms of the Social and Clinical Risk Factors of Respiratory Syncytial Virus Infection in Northern Canada;Cureus;2024-02-01

2. Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants;Frontiers in Pediatrics;2024-01-12

3. Respiratory syncytial virus and metapneumovirus;Molecular Medical Microbiology;2024

4. Immunity towards human respiratory syncytial virus;Acta Virologica;2023-08-24

5. A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age;PLOS ONE;2023-08-10